BioNTech Yönetim

Yönetim kriter kontrolleri 4/4

BioNTech CEO'su Ugur Sahin, Jan2008 tarihinde atandı, in görev süresi 16.83 yıldır. in toplam yıllık tazminatı € 3.06M olup, şirket hissesi ve opsiyonları dahil olmak üzere 22.9% maaş ve 77.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 17.23% ine doğrudan sahiptir ve bu hisseler $ 4.67B değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.3 yıl ve 4.6 yıldır.

Anahtar bilgiler

Ugur Sahin

İcra Kurulu Başkanı

€3.1m

Toplam tazminat

CEO maaş yüzdesi	22.9%
CEO görev süresi	16.8yrs
CEO sahipliği	17.2%
Yönetim ortalama görev süresi	3.3yrs
Yönetim Kurulu ortalama görev süresi	4.6yrs

Son yönetim güncellemeleri

Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year

May 11

Recent updates

BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold

Nov 06

BioNTech SE Just Reported A Surprise Profit And Analysts Updated Their Estimates

Nov 06

BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise

Aug 06

Improved Revenues Required Before BioNTech SE (NASDAQ:BNTX) Shares Find Their Feet

Jun 16

BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical

Jun 13

Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year

May 11

Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report

May 08

BioNTech Earnings Preview: I Will Stay On The Sidelines

May 03

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Apr 22

We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings

Mar 27

BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Mar 24

BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions

Mar 20

BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time

Feb 23

BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

Feb 09

Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Jan 18

Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price

Jan 02

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Dec 11

Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook

Oct 22

BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet

Sep 11

Is BioNTech (NASDAQ:BNTX) A Risky Investment?

Jun 13

A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)

May 23

BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates

Mar 29

CEO Tazminat Analizi

Ugur Sahin'un ücretlendirmesi BioNTech'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-€467m
Jun 30 2024	n/a	n/a	-€504m
Mar 31 2024	n/a	n/a	€113m
Dec 31 2023	€3m	€700k	€930m
Sep 30 2023	n/a	n/a	€3b
Jun 30 2023	n/a	n/a	€4b
Mar 31 2023	n/a	n/a	€6b
Dec 31 2022	€6m	€360k	€9b
Sep 30 2022	n/a	n/a	€10b
Jun 30 2022	n/a	n/a	€12b
Mar 31 2022	n/a	n/a	€13b
Dec 31 2021	€12m	€360k	€10b
Sep 30 2021	n/a	n/a	€7b
Jun 30 2021	n/a	n/a	€4b
Mar 31 2021	n/a	n/a	€1b
Dec 31 2020	€17m	€360k	€15m
Sep 30 2020	n/a	n/a	-€410m
Jun 30 2020	n/a	n/a	-€230m
Mar 31 2020	n/a	n/a	-€192m
Dec 31 2019	€7m	€311k	-€179m
Sep 30 2019	n/a	n/a	-€122m
Jun 30 2019	n/a	n/a	-€116m
Mar 31 2019	n/a	n/a	-€77m
Dec 31 2018	€653k	€210k	-€48m

Tazminat ve Piyasa: Ugur 'nin toplam tazminatı ($USD 3.18M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 12.66M ).

Tazminat ve Kazançlar: Ugur 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Ugur Sahin (59 yo)

16.8yrs

Görev süresi

€3,056,000

Tazminat

Prof. Dr. Ugur Sahin, MD, is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its Member of Management Board since 2008 and serves as its Chair of the Management Board. Pr...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ugur Sahin	Co-Founder	16.8yrs	€3.06m	17.23% $ 4.7b
Ozlem Tureci	Co-Founder	6.8yrs	€814.00k	0.38% $ 103.3m
Jens Holstein	CFO & Member of Management Board	3.3yrs	€1.32m	0.00068% $ 184.4k
Sierk Poetting	MD, COO & Member of Management Board	10.8yrs	€821.00k	0.31% $ 85.4m
Ryan Richardson	Chief Strategy Officer	4.8yrs	€1.41m	0.0061% $ 1.7m
James Timothy Ryan	Chief Legal & Business Officer & Member of the Management Board	1.2yrs	€848.00k	Veri yok
Sean Marett	Executive Officer	less than a year	€133.00k	0.34% $ 92.2m
Lisa Birringer	Senior Vice President of Global Financial Reporting & Accounting	less than a year	Veri yok	Veri yok
Zach Taylor	Senior Vice President of Corporate Development & Strategy	less than a year	Veri yok	Veri yok
Katalin Kariko	Senior VP & External Consultant for RNA Protein Replacement Therapies	no data	Veri yok	Veri yok
Oliver Henning	Senior Vice President of Operations	no data	Veri yok	Veri yok
Sebastian Kreiter	Senior Vice President of Immunotherapy & Preclinical Research	no data	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: BNTX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Rudolf Staudigl	Supervisory Board Member	2.4yrs	€90.00k	0.00017% $ 46.1k
Ulrich Wandschneider	Independent Deputy Chairman Supervisory Board	6.8yrs	€114.00k	Veri yok
Michael Motschmann	Independent Supervisory Board Member	16.8yrs	€80.00k	Veri yok
Helmut Jeggle	Independent Supervisory Board Chairman	16.8yrs	€226.00k	0.14% $ 37.6m
Nicola Blackwood	Member of Supervisory Board	1.5yrs	€46.00k	Veri yok
Anja Morawietz	Supervisory Board Member	2.4yrs	€105.00k	0.00010% $ 27.1k

4.6yrs

Ortalama Görev Süresi

58.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BNTX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.6 yıldır).

BioNTech Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

BioNTech SE, Annual General Meeting, May 17, 2024

Independent Supervisory Board Chairman notifies of intention to sell stock

BioNTech Appoints James Ryan as Chief Legal Officer Effective September 1, 2023

Recent updates

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.

Consensus EPS estimates fall by 15%

BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold

BioNTech SE Just Reported A Surprise Profit And Analysts Updated Their Estimates

Second quarter 2024 earnings released: €3.36 loss per share (vs €0.79 loss in 2Q 2023)

New major risk - Revenue and earnings growth

BioNTech SE to Report Q3, 2024 Results on Nov 04, 2024

BioNTech's Oncology Gamble: High Stakes, Big Potential

BioNTech and OncoC4 Announce U.S. Food and Drug Administration Placed A Partial Clinical Hold on the Two-Stage, Open-Label, Randomized Phase 3 Trial, PRESERVE-003 (NCT05671510)

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron KP.2-Adapted Covid-19 Vaccine in the European Union

Consensus EPS estimates fall by 10%

New major risk - Revenue and earnings growth

BioNTech SE (NASDAQ:BNTX) Shares Fly 27% But Investors Aren't Buying For Growth

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval & Authorization for Omicron KP.2-Adapted COVID-19 Vaccine

BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward

Pfizer and BioNTech Provide Update on mRNA -Based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

Consensus EPS estimates fall by 24%

University of Pennsylvania Files A Lawsuit Against BioNTech SE and Biontech Rna Pharmaceuticals GmbH

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise

BioNTech SE Reiterates Earnings Guidance for the Year 2024

BioNTech SE to Report Q2, 2024 Results on Aug 05, 2024

Improved Revenues Required Before BioNTech SE (NASDAQ:BNTX) Shares Find Their Feet

BioNTech: Managements Wants 10 Oncology Drug Approvals By 2030, I'm Skeptical

New minor risk - Earnings quality

New major risk - Revenue and earnings growth

Consensus EPS estimates upgraded to €1.74 loss

Here's Why BioNTech SE's (NASDAQ:BNTX) CEO May Not Expect A Pay Rise This Year

Analyst Estimates: Here's What Brokers Think Of BioNTech SE (NASDAQ:BNTX) After Its First-Quarter Report

BioNTech SE Reiterates Revenue Guidance for the Full Year 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

BioNTech Earnings Preview: I Will Stay On The Sidelines

BioNTech SE to Report Q1, 2024 Results on May 06, 2024

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

Consensus EPS estimates fall by 11%

We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings

Consensus EPS estimates have been downgraded.

BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions

Now 21% undervalued after recent price drop

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time

BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Initiate Pivotal Phase 3 Trial of Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Metastatic Breast Cancer

Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%

Robbins LLP Informs Investors of Class Action Filed Against BioNTech SE

Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price

BioNTech and Duality Biologics (Suzhou) Co. Ltd. Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Endometrial Cancer

BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Aexerna Therapeutics.

BioNTech SE to Report Q4, 2023 Results on Mar 20, 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Pfizer Inc. and BioNTech SE Announce Positive Topline Data for MRNA-Based Combination Vaccine Program Against Influenza and Covid-19

Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook

BioNTech SE, Annual General Meeting, May 17, 2024

BioNTech SE Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-Based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

New major risk - Revenue and earnings growth

Consensus EPS estimates fall by 13%

Independent Supervisory Board Chairman notifies of intention to sell stock

Curevac Reports Progress in Intellectual Property Infringement Case Against Biontech in Germany

Pfizer and Biontech Receive Health Canada Authorization for Xbb.1.5-Adapted Monovalent Covid-19 Vaccine

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet

Investor sentiment improves as stock rises 17%